Lise Mangiante
Overview
Explore the profile of Lise Mangiante including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
103
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Greenwald N, Nederlof I, Sowers C, Ding D, Park S, Kong A, et al.
bioRxiv
. 2025 Feb;
PMID: 39975273
Immune checkpoint inhibition (ICI) has fundamentally changed cancer treatment. However, only a minority of patients with metastatic triple negative breast cancer (TNBC) benefit from ICI, and the determinants of response...
2.
Houlahan K, Mangiante L, Sotomayor-Vivas C, Adimoelja A, Park S, Khan A, et al.
Nature
. 2025 Jan;
638(8050):510-518.
PMID: 39779850
Breast cancer is a highly heterogeneous disease whose prognosis and treatment as defined by the expression of three receptors-oestrogen receptor (ER), progesterone receptor and human epidermal growth factor receptor 2...
3.
Zhang S, Valenzuela L, Zatulovskiy E, Mangiante L, Curtis C, Skotheim J
Sci Adv
. 2024 Oct;
10(43):eadq6858.
PMID: 39441926
Mammalian cells make the decision to divide at the G-S transition in response to diverse signals impinging on the retinoblastoma protein Rb, a cell cycle inhibitor and tumor suppressor. Passage...
4.
Alcala N, Voegele C, Mangiante L, Sexton-Oates A, Clevers H, Fernandez-Cuesta L, et al.
Gigascience
. 2024 Mar;
13.
PMID: 38451475
Background: Organoids are 3-dimensional experimental models that summarize the anatomical and functional structure of an organ. Although a promising experimental model for precision medicine, patient-derived tumor organoids (PDTOs) have currently...
5.
Dayton T, Alcala N, Moonen L, den Hartigh L, Geurts V, Mangiante L, et al.
Cancer Cell
. 2023 Dec;
41(12):2083-2099.e9.
PMID: 38086335
Neuroendocrine neoplasms (NENs) comprise well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Treatment options for patients with NENs are limited, in part due to lack of accurate models....
6.
Zhang S, Valenzuela L, Zatulovskiy E, Mangiante L, Curtis C, Skotheim J
bioRxiv
. 2023 Oct;
PMID: 37873473
Mammalian cells make the decision to divide at the G1/S transition in response to diverse signals impinging on the retinoblastoma protein Rb, a cell cycle inhibitor and tumor suppressor. Rb...
7.
Mangiante L, Alcala N, Sexton-Oates A, Di Genova A, Gonzalez-Perez A, Khandekar A, et al.
Nat Genet
. 2023 Mar;
55(4):607-618.
PMID: 36928603
Malignant pleural mesothelioma (MPM) is an aggressive cancer with rising incidence and challenging clinical management. Through a large series of whole-genome sequencing data, integrated with transcriptomic and epigenomic data using...
8.
Di Genova A, Mangiante L, Sexton-Oates A, Voegele C, Fernandez-Cuesta L, Alcala N, et al.
Gigascience
. 2023 Jan;
12.
PMID: 36705549
Background: Malignant pleural mesothelioma (MPM) is a rare understudied cancer associated with exposure to asbestos. So far, MPM patients have benefited marginally from the genomics medicine revolution due to the...
9.
Moonen L, Mangiante L, Leunissen D, Lap L, Gabriel A, Hillen L, et al.
Int J Cancer
. 2022 Jan;
150(12):1987-1997.
PMID: 35076935
Limited number of tumor types have been examined for Orthopedia Homeobox (OTP) expression. In pulmonary carcinoids, loss of expression is a strong indicator of poor prognosis. Here, we investigated OTP...
10.
Fernandez-Cuesta L, Mangiante L, Alcala N, Foll M
Virchows Arch
. 2021 Jan;
478(1):73-80.
PMID: 33411030
The diagnosis and classification of malignant pleural mesothelioma (MPM) is extremely challenging; obtaining an accurate histopathological diagnosis of the different types and subtypes requires expert assessment and suitable biopsies that...